In summary, our study demonstrated that decreased HDAC7 expression was correlated with poor prognosis and immune infiltration in DLBCL, which may provide crucial information for the development of novel immunotherapies. The gene discussed is HDAC7; the disease is diffuse large B-cell lymphoma.